A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
Abstract | OBJECTIVE: METHODS: RESULTS: Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% [P < 0.0001]), as well as at 3 months (92.9% versus 13.8% [P < 0.0001]), 6 months (71.4% versus 3.5% [P < 0.0001]), and 24 months (60.7% versus 3.5% [P < 0.0001]). The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean ± SD of 11.9 ± 5.4 at baseline to 7.1 ± 5.7 at month 2; P < 0.001) up to month 24 (4.4 ± 4.6; P < 0.0001). RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The median duration of response to RTX was 18 months. Overall, RTX treatment was well tolerated. CONCLUSION: RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
|
Authors | S De Vita, L Quartuccio, M Isola, C Mazzaro, P Scaini, M Lenzi, M Campanini, C Naclerio, A Tavoni, M Pietrogrande, C Ferri, M T Mascia, P Masolini, A Zabotti, M Maset, D Roccatello, A L Zignego, P Pioltelli, A Gabrielli, D Filippini, O Perrella, S Migliaresi, M Galli, S Bombardieri, G Monti |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 64
Issue 3
Pg. 843-53
(Mar 2012)
ISSN: 1529-0131 [Electronic] United States |
PMID | 22147661
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 by the American College of Rheumatology. |
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Antiviral Agents
- Glucocorticoids
- Immunologic Factors
- Rituximab
- Cyclophosphamide
- Azathioprine
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Azathioprine
(therapeutic use)
- Combined Modality Therapy
- Cryoglobulinemia
(complications, pathology, therapy)
- Cyclophosphamide
(therapeutic use)
- Drug Resistance, Viral
(drug effects)
- Drug Substitution
- Drug Therapy, Combination
- Female
- Glucocorticoids
(therapeutic use)
- Hepatitis C, Chronic
(complications, drug therapy)
- Humans
- Immunologic Factors
(therapeutic use)
- Male
- Middle Aged
- Plasmapheresis
- Remission Induction
- Rituximab
- Severity of Illness Index
- Treatment Outcome
- Young Adult
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|